华润紫竹药业有限公司

What 华润紫竹药业有限公司 does

China Resources Zizhu Pharmaceutical Co., Ltd. (华润紫竹药业有限公司) is a Beijing-headquartered state-owned pharmaceutical manufacturer organized under China Resources Shuanghe Pharmaceutical Co., Ltd., with operations spanning research and development, API production, finished-dose formulation, and channel marketing. Founded in 1969 as Beijing Third Pharmaceutical Factory and rebranded in 1999, the company has accumulated 50+ years of specialization in women's health and reproductive medicine, anchored by the Yuting (毓婷) levonorgestrel-based emergency contraceptive brand, which has held category leadership for 24 years and serves as a designated reproductive health drug supplier to the United Nations Population Fund (UNFPA).

The company's technology backbone is a vertically integrated steroid hormone platform that spans chemical synthesis, biotransformation, formulation R&D, and quality research, with two primary industrial sites: a 300-mu EU-GMP-certified API base in Qinhuangdao (Hebei) producing steroid hormone APIs such as levonorgestrel, ethinyl estradiol, and estradiol — seven of which hold CEP certificates for sale across all 28 EU member states — and a finished-formulation plant in Beijing certified under Chinese GMP, WHO GMP, EU GMP, and Mexican official GMP regimes. The marketed product portfolio extends beyond emergency contraceptives (Yuting, Jin Yuting) and medical abortion products (Mifepristone, passed national consistency evaluation) into ophthalmology (Compound Anisodine Hydrobromide Injection, Latanoprost eye drops), oral care (Zizhu Propolis Oral Membrane), diabetes (Epalrestat tablets), perinatal nutrition (朴美 series), and the latex medical device business operated through a Guilin subsidiary.

Commercially, Zizhu runs a hybrid distribution model combining traditional pharmacy channels — anchored by KA chain partnerships with Yuxipingmin, Haiwangxingchen, Guoda Pharmacy, Lao Baixing, Yifeng, Dashenlin, and Yixin Tang — with newer O2O/e-commerce routes through Ele.me, Meituan, JD, and Tmall, plus a co-built enablement platform (品立方俱乐部) with Tianjin Zhongxin Pharmaceutical targeting new retail. Customer acquisition is supported by long-running brand-building programs such as the Zizhu Youth Health Campus Walk (covering 30+ provinces, 500+ universities, and 2.5 million+ college students since 2005) and the Zizhu Women's Health China Walk initiative. Pricing is not publicly disclosed; products are sold as prescription drugs and OTC through pharmacies and hospital channels, with international API sales conducted directly to 100+ industrial customers in 20+ countries.

Name

华润紫竹药业有限公司

Legal name

华润紫竹药业有限公司

Website

https://zizhu-pharm.com.cn

Company type

Private

Founded year

1969

Operating status

Operating

Headcount range

51–100 employees

Short description

China Resources Zizhu Pharmaceutical (华润紫竹药业) is a Beijing-headquartered state-owned pharmaceutical company specializing in women's reproductive health, manufacturing emergency contraceptives (Yuting brand), mifepristone, ophthalmic and diabetes medicines, plus steroid hormone active pharmaceutical ingredients exported to the EU and 20+ countries.

Ownership category

akta.pro rank

Product category

Women's Health Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Ophthalmology Pharmaceuticals (HLAIAAAL), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Women's health pharmaceuticals
• Reproductive health products
• Emergency contraception
• Active pharmaceutical ingredients
• Oral care products

Headquarters

HQ city

北京市, 北京市

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. 女性健康用药及器械: 主导产品紧急避孕药毓婷、金毓婷、抗早孕药米非司酮等女性健康用药的销售，以及相关医疗器械产品
2. 口腔用药: 紫竹蜂胶口腔膜等口腔护理产品
3. 眼科用药: 复方樟柳碱注射液、拉坦前列素滴眼液等眼科制剂产品
4. 糖尿病用药: 紫竹万安依帕司他片等糖尿病治疗药物
5. 原料药: 甾体激素类原料药生产销售，包括左炔诺孕酮、炔雌醇、雌二醇等7个原料药获得CEP证书，3个WHO预资质认证
6. 乳胶业务: 桂林紫竹乳胶厂生产的乳胶产品

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

华润紫竹药业有限公司 is a pharmaceutical manufacturer that develops, produces, and sells branded women's health products (most notably the 毓婷/金毓婷 emergency contraception line), oral care products (紫竹蜂胶口腔膜), ophthalmic preparations, diabetes medications, and downstream latex medical devices. It also manufactures and exports Active Pharmaceutical Ingredients (APIs) to international pharmaceutical clients as a B2B supplier.

Product overview

华润紫竹药业有限公司 is a state-owned high-tech pharmaceutical company integrating R&D, manufacturing, and marketing. The company focuses on women's health and has developed a multi-product portfolio centered around reproductive health medications (emergency contraceptives like 毓婷 and 金毓婷, anti-early pregnancy drugs like 米非司酮), complemented by oral care (紫竹蜂胶口腔膜), ophthalmic products (复方樟柳碱注射液, 拉坦前列素滴眼液), diabetes treatments (紫竹万安/依帕司他片), prenatal nutrition supplements (朴美 series), active pharmaceutical ingredients (原料药), and latex medical devices (乳胶业务). The company operates under a "one-axis-two-wings" strategic layout and serves as a UNFPA reproductive health drug supplier.

Differentiator

Problem solved

Functional benefit

Brands

• 毓婷: 紧急避孕药品牌（左炔诺孕酮片）
• 金毓婷
• 朴美

Products and services

• 毓婷 (Yuting) Over-the-counter emergency contraception product for adult women in China, sold through pharmacies, hospitals, and e-commerce platforms such as JD, Tmall, and Meituan.
• 金毓婷 (Jin Yuting) Premium-tier emergency contraception product offered as a higher-end variant in the 毓婷 brand family for adult women in China.
• 朴美 (Pu Mei) Consumer health product in the women's health and beauty category, positioned for Chinese female consumers.
• 紫竹蜂胶口腔膜 (Zizhu Propolis Oral Film) Propolis-based oral care/film product for the consumer oral health market in China.
• Active Pharmaceutical Ingredients (APIs) Bulk Active Pharmaceutical Ingredients manufactured for B2B sale to international pharmaceutical companies, with 7 APIs certified under CEP for sale in EU 28 member states and additional WHO, EU, and Mexico GMP certifications.
• Latex medical devices Latex-based medical devices manufactured by the Guilin subsidiary for clinical and consumer use.
• Reproductive health drugs for UNFPA Reproductive health drugs supplied to UNFPA and similar international public health organizations for distribution in low-resource countries.

Quantifiable outcome

• 毓婷品牌已为逾六亿多人次的女性提供了有效、安全的健康关爱
• +2 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature4 records

Scale indicators12 records

Recent moves10 records

Expansion highlights5 records

Broad incumbents

• Shanghai Pharmaceuticals Holding: One of China's largest state-owned pharmaceutical conglomerates with broad pharmaceutical and API operations. Comparable as a peer in China's SOE pharmaceutical ecosystem with both branded and API businesses.
• Bayer (Consumer Health): Global OTC giant with established women's health portfolio including contraception products. Comparable as a large incumbent operating in the same therapeutic categories with broader scale and international distribution.
• Sino Biopharmaceutical: Major Chinese pharmaceutical group with significant market share in women's health, oncology, and other therapeutic areas. Comparable as a peer in women's health and steroid hormone manufacturing.
• China Resources Double-Crane Pharmaceutical: Parent company of 紫竹药业 and a major Chinese SOE pharmaceutical group with diversified women's health and hormone products. Comparable as a peer in scale and product overlap, with 紫竹 as a wholly-owned subsidiary.
• Shanghai Fosun Pharmaceutical: Diversified Chinese pharmaceutical group with significant women's health and API manufacturing operations. Comparable as a similarly-sized Chinese pharma company with both branded generics and international API exports.

Direct peers

• HRA Pharma (Perrigo): Developer of ellaOne (ulipristal acetate), the leading second-generation emergency contraceptive competing directly with 毓婷 in China and global markets. Comparable as a reproductive-health-focused pharmaceutical company with strong consumer brand recognition.
• Hologic: Markets Mifeprex (mifepristone) for medical abortion in the US, directly comparable to 紫竹's mifepristone franchise. Both compete in the same active ingredient and indication across different geographies.
• Organon: Global women's health-focused pharmaceutical company spun off from Merck, with leading contraception, fertility, and menopause therapy franchises. Directly comparable as a women's health pure-play with similar therapeutic focus areas.

Regional players

• Yunnan Baiyao: Leading Chinese pharmaceutical and consumer health company with adjacent OTC and specialty pharma portfolios. Comparable as a Chinese pharmaceutical peer with branded consumer health products and nationwide distribution.
• Lupin Pharmaceuticals: India-based global pharmaceutical manufacturer with strong steroid hormone and women's health API capabilities. Comparable as a peer in hormone API manufacturing and women's health generics, but primarily serving different geographic markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/%E5%8D%8E%E6%B6%A6%E7%B4%AB%E7%AB%B9%E8%8D%AF%E4%B8%9A%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 华润紫竹药业有限公司